tiprankstipranks
Trending News
More News >

Clover Biopharmaceuticals Initiates U.S. Clinical Trial for RSV Vaccine Candidate

Story Highlights
Clover Biopharmaceuticals Initiates U.S. Clinical Trial for RSV Vaccine Candidate

Don’t Miss TipRanks’ Half-Year Sale

Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has issued an announcement.

Clover Biopharmaceuticals Ltd. announced the U.S. FDA clearance for its Investigational New Drug application and the initiation of a Phase I revaccination clinical trial for its RSV vaccine candidate, SCB-1019. This trial, enrolling older adults who previously received GSK’s RSV vaccine, aims to evaluate the safety and immunogenicity of SCB-1019. The company is also planning a Phase I trial in 2025 for a combination vaccine involving RSV and other respiratory viruses, indicating its strategic expansion in the vaccine market.

More about Clover Biopharmaceuticals Ltd.

Clover Biopharmaceuticals Ltd. is a company in the biotechnology industry, focusing on the development of innovative vaccines and biologics. It utilizes its proprietary Trimer-Tag vaccine technology platform to create vaccine candidates, with a market focus on addressing infectious diseases.

YTD Price Performance: 34.85%

Average Trading Volume: 1,618,911

Technical Sentiment Signal: Hold

Current Market Cap: HK$421.5M

Find detailed analytics on 2197 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1